The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment -- with no signs of additional safety risks, a new study finds. Gleevec -- known generically as imatinib ...
Gleevec contains the drug imatinib, which belongs to a class of drugs called tyrosine kinase inhibitors (TKIs). Medications in the TKI drug class are targeted therapies. They affect specific proteins ...
Nonadherence to Gleevec in GIST patients is common, with cognitive functioning, TDM, and social support as key indicators. A machine learning model using 64 covariates identified 19 significant ...
Gleevec (imatinib mesylate) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved Gleevec to treat the following blood cancers in certain situations: Gleevec ...
Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...
For decades, medical science has developed new treatments and medications to battle cancer, cautiously hoping that somewhere out there lies a "magic bullet"--a cure. Several weeks ago, for a time, it ...
The fundamental importance of protein kinases is indisputable. Their central role in essential physiological processes has provoked extensive studies and has resulted in a wealth of knowledge from ...
Novartis' first rule of innovation -- forget the forecasts, focus on the science. In the video below, analyst Max Macaluso and Bernard Munos, founder of the InnoThink Center for Research in Biomedical ...
FRIDAY, May 19, 2017 -- A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests. Gleevec (imatinib) reduced the "twitchiness" of airways, making them less ...
Everyone hopes and wishes for that last-minute cancer breakthrough that will save doomed patients. It almost never actually happens. With Gleevec, it did. The once-a-day pill turned chronic ...
- Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic filings EAST HANOVER, N.J., August 27, 2008 ...
The team notes, "Taken together, Gleevec exhibits greater beneficial effects on both glucose/lipid metabolism and energy homeostasis by blocking PPARĪ³ phosphorylation." They continue, "These data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback